###### Strengths and limitations of this study

-   First comprehensive study on the direct medical costs of type 2 diabetes in the Philippines.

-   Triangulation of multiple data sources, including both databases and physician interviews.

-   Selection of hospitals is not representative of all hospitals in the Philippines.

Introduction {#s1}
============

Type 2 diabetes has become one of the most challenging public health issues globally. The prevalence of diabetes quadrupled from 108 million persons in 1980 to 422 million persons in 2014.[@R1] Rising prevalence of complications was also observed.[@R2] In the Philippines, the number of people with diabetes has increased from 3.4 million in 2010[@R3] to 3.7 million in 2017.[@R4] Each day, there are at least 100 deaths due to diabetes-related acute or chronic complications.[@R5] According to a survey conducted in 2008, among 770 Filipinos with diabetes who were recruited from general hospitals, diabetes clinics and referral clinics, 85% of the patients had uncontrolled diabetes[@R6] with haemoglobin A1c \>7.0%.[@R7] Almost all patients (99%) had cardiovascular complications. Other common complications included foot complications (82%), nephropathy (81%), neuropathy (67%) and eye complications (62%).

The cost burden of diabetes particularly affects patients in low-income and middle-income countries.[@R8] The presence of complications could also potentially increase the medical expenditure, which has a profound impact on the direct health system costs of diabetes.[@R9] The International Diabetes Federation (IDF) reported that the mean overall diabetes-related expenditure per person with diabetes in the Philippines has increased from US\$61 in 2010[@R3] to US\$234 in 2017, indicating a growing financial burden.[@R4] However, detailed and comprehensive cost data for diabetes and its complications remain scant and fragmented.[@R3] Average costs of a few direct medical and indirect cost components were reported in a study conducted among 359 respondents recruited from different levels of healthcare settings in 2008. Oral medications, insulin and transportation cost per visit were reported to be US\$13/month, US\$20/month and US\$1/visit, respectively.[@R12] Other components of direct medical costs, such as laboratory tests and procedures, were not part of the research scope.

Healthcare and financing in the Philippines are fragmented and varied.[@R13] Estimating the burden of chronic diseases could be challenged by the presence of multiple morbidities and the lack of reliable and publicly available data sources. The current arsenal of costing methodologies is also limited to infectious diseases,[@R14] or inpatient costing[@R16] from the use of the PhilHealth database, and may not be suitable for estimating the burden of chronic diseases. Therefore, this study methodology aims to detail the methodology for estimating the direct medical costs of type 2 diabetes mellitus (T2DM) in the Philippines.

Methods and analysis {#s2}
====================

A prevalence-based approach using the healthcare system perspective will be used to estimate the annual direct medical costs of diabetes management in the Philippines in 2016.[@R17] Data will be collected from hospital electronic health records (EHR) and physician interviews. Results will be reported according to the REporting of studies Conducted using Observational Routinely-collected Data statement.[@R18]

Patient and public involvement {#s2-1}
------------------------------

No patients are involved throughout the study.

Description of data sources {#s2-2}
---------------------------

Data will be extracted by the respective institutions, excluding patients' identifiable details such as names, identification numbers, addresses and dates of birth, as per Data Privacy Act of 2012.[@R19] Methodology on the estimation of the annual cost per capita for patients with and without complications is summarised in [figure 1](#F1){ref-type="fig"}.

![Sources of cost data for each group of patients with T2DM. DSCI, Diabetes Severity Complications Index; ICD, International Statistical Classification of Diseases; T2DM, type 2 diabetes mellitus.](bmjopen-2018-025696f01){#F1}

1.  Hospital databases will be used to estimate the prevalence and cost of diabetes and its complication*s.* Data will be obtained from the Ospital ng Makati (ONM; 300-bed, tertiary or level 3 public hospital) in Makati City, Metro Manila and the National Kidney and Transplant Institute (NKTI; 400-bed, level 3 referral public hospital which also provides private healthcare services) in Quezon City, Metro Manila. General hospitals in the Philippines are categorised into different levels based on functional capacity. Level 3 hospitals have the most advanced technology and are concentrated in Metro Manila and Central Luzon. Level 1 hospitals are well-distributed throughout the country but have more limited resources.[@R13] These two hospitals were selected because of their good availability and quality of data due to their EHR systems. These databases were also assessed based on the 3×3 data quality assessment. The profile of eligible patients will include those who are national citizens, aged 18 or above, and are diagnosed with T2DM. Patients with T2DM will be identified by the 10th revision of the International Statistical Classification of Diseases (ICD-10) code E11 from the database of NKTI. Specific keywords from the list of diagnoses in the Diabetes Severity Complications Index (DSCI) and algorithms are used to search for patients with T2DM and its complications from the free-text diagnosis in the database of ONM. This data extraction is conducted by two independent coders using different algorithms. A reviewer will then reconcile the differences in coding. [Table 1](#T1){ref-type="table"} outlines the variables to be extracted from all hospital databases.

2.  Physician interviews will be used to estimate the resource utilisation of patients seeking diabetes care in outpatient settings. It is more important to provide validity and insights on outpatient diabetes care instead of being representative of all physicians in the Philippines. Therefore, the study will use a purposive sampling of 50 physicians to achieve the diversity of institutions/clinics in Metro Manila. In the Philippines, patients receive diabetes care mainly from endocrinologists, diabetologists, internal medicine doctors or family medicine doctors. Interviews will be conducted with endocrinologists, diabetologists, internal medicine doctors and family medicine doctors in Makati City and Quezon City within Metro Manila to capture the cost of diabetes care comparable to the data collected from ONM and NKTI, respectively. Survey questions will include typical resource utilisation of patients seeking diabetes consultations, such as frequency of visits and monitoring tests. [Table 2](#T2){ref-type="table"} shows the distribution of 24 physicians who will be recruited from Makati City and 26 physicians from Quezon City. Physicians will be recruited from IQVIA's master list of physicians via telephone calls. The eligibility criteria for participation in the survey include the following: at least 8 years of experience in the speciality or 15 years in family medicine; at least 5 years of practice in private outpatient hospital or clinic and treating at least a hundred individuals with diabetes per month. Physicians will be explained the purpose and procedures of the study, and those who agree will provide written informed consent. Interviews will be conducted face-to-face and are expected to last 30 to 45 minutes each.

###### 

Variables to be extracted from hospital databases

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable                                                                                     Scale         Unit                                        Records to extract during study time period
  -------------------------------------------------------------------------------------------- ------------- ------------------------------------------- -------------------------------------------------------------------------------------
  Patient (pseudo)identifier                                                                   Categorical   Unique patient ID as recorded in database   Record at the index

  Age at index                                                                                 Numerical     years                                       Record at or closest to the index

  Gender                                                                                       Categorical   0=female, 1=male                            Record at or closest to the index

  Glycated haemoglobin (HbA1c)                                                                 Continuous    \%                                          All records during the study period

  Blood glucose levels                                                                         Continuous    mmol/L                                      All records during the study period

  Triglyceride levels                                                                          Continuous    mg/dL                                       All records during the study period

  LDL/HDL                                                                                      Continuous    No units                                    All records during the study period

  Serum creatinine                                                                             Continuous    µmol/L                                      All records during the study period

  UACR                                                                                         Continuous    mg                                          All records during the study period

  Dyslipidaemia                                                                                Character     ICD-10 codes                                All records from the database

  Hypertension                                                                                 Character     ICD-10 codes                                All records from the database

  Name of drugs prescribed                                                                     Character     Name of pre-specified drug in database      All records during the study period

  Date of drugs prescribed                                                                     Date          dd/mm/yyyy                                  All records during the study period

  Quantity of drug prescribed                                                                  Continuous    As noted                                    All records during the study period

  Strength of drug prescribed (dose)                                                           Continuous    As noted mg                                 All records during the study period

  Costs of drug prescribed                                                                     Continuous    PHP                                         All records during the study period

  Date and type of healthcare resource use (eg, GP visits, hospitalisation/ICU/discharge/ER)   Continuous    dd/mm/yyyy                                  All records during the study period

  Procedures                                                                                   Categorical   ICD-9-CM                                    All records during the study period

  Laboratory tests                                                                             Categorical   As noted                                    All records during the study period

  Costs of healthcare resource use (eg, GP visits, hospitalisation, medical supplies)          Continuous    PHP                                         All records during the study period\
                                                                                                                                                         (medications, outpatient services, emergency visits and inpatient hospitalisations)

  Professional fees                                                                            Continuous    PHP                                         All records in the database

  Diagnosis of complications, as per DSCI                                                      Categorical   ICD-10 codes                                All records during the study period
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

DSCI, Diabetes Severity Complications Index; ER, emergency room; GP, General Practice; HDL, high-density lipoprotein; ICD, International Statistical Classification of Diseases; ICU, Intensive Care Unit; LDL, low-density lipoprotein; PHP, Philippine Peso; UACR, urine albumin-to-creatinine ratio.

###### 

Sample distribution for physician interviews

                         Endocrinology   Diabetology   Family medicine   Internal medicine   Total
  ---------------------- --------------- ------------- ----------------- ------------------- -------
  Makati city                                                                                
    Public facilities    2               2             2                 2                   8
    Private facilities   6               6             2                 2                   16
  Total                  8               8             4                 4                   24
  Quezon city                                                                                
    Public facilities    2               2             2                 2                   8
    Private facilities   8               6             2                 2                   18
  Total                  10              8             4                 4                   26
  Overall total          18              16            8                 8                   50

Outcomes {#s2-3}
--------

The outcome of interest is the mean direct medical costs in patients with diabetes complications and those without complications.

Direct medical costs of patients with and without complications will be estimated.

1.  Diabetes with complications. Annual health expenditure per patient would be calculated from patients identified with complications, as outlined in the DSCI. This group of patients will be further categorised into patients with and without hospitalisation records in the year 2016.

2.  Diabetes without complications. The annual cost of each patient without complications is determined from the hospital databases and the physician interviews. In the latter, physicians will estimate the resources needed to manage patients with diabetes and comorbidities, namely hypertension and dyslipidaemia. Resource utilisation will be multiplied by average unit costs to estimate the per capita cost for each patient group: (a) diabetes only, (b) diabetes and hypertension, (c) diabetes and dyslipidaemia and (d) diabetes, hypertension and dyslipidaemia. Unit costs of treatment and tests will be obtained from the administrator or fee schedule of each physician's affiliated institution/clinic.

Data management {#s2-4}
---------------

The dataset from each institution will be managed independently. Resource utilisation will be standardised across each institution and categorised into the following: drugs, procedures, dialysis, surgery, supplies and others.

Strengths and limitations {#s2-5}
-------------------------

Although this study is fortified with data from the leading hospitals in the Philippines, with complete electronically captured data, it is not without limitations. Generalisability of this study could be limited by the selection of hospitals, as they may not be representative of all hospitals in the Philippines. These hospitals provide tertiary care and are mainly serving as referral centres in Manila. Hence, these institutions are more likely to see patients with more severe conditions. Another limitation could be the possibility of missing out T2DM patients whose diagnoses did not include T2DM. However, this is unlikely to affect the average cost, as the absence of the T2DM diagnosis is not related to any outcome. Future studies should include more hospitals to improve the generalisability of the study findings.

Ethics and dissemination {#s2-6}
------------------------

Ethics approval has been obtained from the Department of Health Single Joint Research Ethics Board and Cardinal Santos Medical Center Research Ethics Review Committee. On study completion and finalisation of the study report, the results of this non-interventional study will be submitted for publication in a scientific journal. Results could also be presented to policymakers or local researchers.
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